celecoxib has been researched along with Precancerous Conditions in 35 studies
Precancerous Conditions: Pathological conditions that tend eventually to become malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 7.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "The expression of the putative markers LGR-5 (leucine-rich-repeat-containing G-protein-coupled receptor 5), MSI-1 (Musashi-1) and DCAMKL-1 (doublecortin and calcium/calmodulin-dependent protein kinase-like-1) was studied in normal colon mucosa (NM), in the precancerous lesions Mucin Depleted Foci (MDF) and in macroscopic tumours (adenomas) of 1,2-dimethylhydrazine-treated rats." | 3.79 | Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin. ( Caderni, G; Dolara, P; Femia, AP; Salvadori, M, 2013) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 3.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE(2), after 12 weeks." | 2.73 | A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. ( Bertagnolli, MM; Dorfman, DM; Goguen, L; Haddad, RI; Krane, JF; Li, Y; Moran, AE; Norris, CM; Othus, M; Posner, MR; Wirth, LJ, 2008) |
| " Because aspirin and other nonsteroidal anti-inflammatory drugs, such as celecoxib, may decrease the risk of developing esophageal cancer, we investigated the effect of long-term administration of celecoxib in patients with Barrett's esophagus with dysplasia." | 2.73 | Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. ( Canto, MI; Dannenberg, AJ; Forastiere, AA; Hawk, E; Heath, EI; Herman, JG; Montgomery, E; Piantadosi, S; Shar, AO; Weinstein, WM; Yang, VW, 2007) |
| "Celecoxib was generally well tolerated." | 2.73 | Pilot randomized phase II study of celecoxib in oral premalignant lesions. ( Atwell, A; Boyle, JO; Dannenberg, AJ; Du, B; El-Naggar, AK; Feng, L; Helman, JI; Lee, JJ; Lippman, SM; Nathan, CO; Ondrey, FG; Papadimitrakopoulou, VA; Peterson, DE; William, WN; Yueh, B, 2008) |
| "Human hepatoma cell lines were treated with lipopolysaccharide (LPS) or cyclooxygenase-2 inhibitor, Celecoxib, and in vitro proliferation, apoptosis, and cell cycle progression were assessed." | 1.39 | Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways. ( Bai, L; Mao, ZY; Su, D; Wang, LJ; Zhang, T, 2013) |
| "Cervical cancer is one of the most common cancers worldwide." | 1.38 | Do NSAIDs inhibit growth of precancerous cervical cells in vitro? ( Charoenvilaisiri, S; Poomkokruk, A; Sakonlaya, D; Tapanadechopone, P, 2012) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| "Celecoxib is a cyclooxygenase-2 inhibitor with significantly less toxicity." | 1.33 | Chemopreventive effect of celecoxib in oral precancers and cancers. ( Feng, L; Wang, Z, 2006) |
| "The ratios of squamous cell carcinomas to papillomas and of sebaceous gland adenomas to papillomas plus squamous cell carcinomas were increased markedly in transgenic mice treated with DMBA alone compared with DMBA/phorbol 12-myristate 13-acetate-treated transgenic and wild-type mice." | 1.31 | Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. ( Berger, I; Furstenberger, G; Marks, F; Muller-Decker, K; Neufang, G; Neumann, M, 2002) |
| " Groups 2 and 3 also received experimental diet containing celecoxib (500 and 1500 ppm, respectively) for 8 weeks, starting a week before the first dosing of AOM." | 1.31 | Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. ( Hara, A; Hirose, Y; Katayama, M; Kuno, T; Mori, H; Qiao, Z; Shimizu, M; Yamada, Y; Yoshimi, N, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (62.86) | 29.6817 |
| 2010's | 13 (37.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DA Costa, RMG | 1 |
| Araújo, R | 1 |
| Santos, JMO | 1 |
| Fernandes, M | 1 |
| Neto, T | 1 |
| Sousa, H | 1 |
| Ribeiro, J | 1 |
| Bastos, MMSM | 1 |
| Oliveira, PA | 1 |
| Carmo, D | 1 |
| Casaca, F | 1 |
| Silva, S | 1 |
| Lopes, C | 1 |
| Medeiros, R | 1 |
| Tołoczko-Iwaniuk, N | 1 |
| Dziemiańczyk-Pakieła, D | 1 |
| Nowaszewska, BK | 1 |
| Celińska-Janowicz, K | 1 |
| Miltyk, W | 1 |
| Mateus, PAM | 1 |
| Kido, LA | 1 |
| Silva, RS | 1 |
| Cagnon, VHA | 1 |
| Montico, F | 1 |
| Wang, LJ | 1 |
| Bai, L | 1 |
| Su, D | 1 |
| Zhang, T | 1 |
| Mao, ZY | 1 |
| Sakonlaya, D | 1 |
| Tapanadechopone, P | 1 |
| Poomkokruk, A | 1 |
| Charoenvilaisiri, S | 1 |
| Balansky, R | 1 |
| Ganchev, G | 1 |
| Iltcheva, M | 1 |
| Nikolov, M | 1 |
| La Maestra, S | 1 |
| Micale, RT | 1 |
| D'Agostini, F | 1 |
| Steele, VE | 2 |
| De Flora, S | 1 |
| Zhang, Y | 1 |
| Pan, KF | 2 |
| Zhang, L | 2 |
| Ma, JL | 2 |
| Zhou, T | 1 |
| Li, JY | 2 |
| Shen, L | 2 |
| You, WC | 2 |
| Falk, GW | 1 |
| Jankowski, J | 1 |
| Hur, C | 1 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 1 |
| Gazelle, GS | 1 |
| Cho, NL | 1 |
| Redston, M | 1 |
| Zauber, AG | 1 |
| Carothers, AM | 1 |
| Hornick, J | 1 |
| Wilton, A | 1 |
| Sontag, S | 1 |
| Nishioka, N | 1 |
| Giardiello, FM | 1 |
| Saltzman, JR | 1 |
| Gostout, C | 1 |
| Eagle, CJ | 1 |
| Hawk, ET | 2 |
| Bertagnolli, MM | 2 |
| Stevens, RG | 1 |
| Pretlow, TP | 1 |
| Hurlstone, DP | 1 |
| Giardina, C | 1 |
| Rosenberg, DW | 1 |
| Wirth, LJ | 1 |
| Krane, JF | 1 |
| Li, Y | 2 |
| Othus, M | 1 |
| Moran, AE | 1 |
| Dorfman, DM | 1 |
| Norris, CM | 1 |
| Goguen, L | 1 |
| Posner, MR | 1 |
| Haddad, RI | 1 |
| Abba, MC | 1 |
| Hu, Y | 1 |
| Levy, CC | 1 |
| Gaddis, S | 1 |
| Kittrell, FS | 1 |
| Hill, J | 1 |
| Bissonnette, RP | 1 |
| Brown, PH | 1 |
| Medina, D | 1 |
| Aldaz, CM | 1 |
| Zhang, LJ | 1 |
| Wang, SY | 1 |
| Huo, XH | 1 |
| Zhu, ZL | 1 |
| Chu, JK | 1 |
| Ma, JC | 1 |
| Cui, DS | 1 |
| Gu, P | 1 |
| Zhao, ZR | 1 |
| Wang, MW | 1 |
| Yu, J | 1 |
| Sohrabi, M | 1 |
| Soleimani, J | 1 |
| Roshangar, L | 1 |
| Vatansever, S | 1 |
| Arbabi, F | 1 |
| Khaki, AA | 1 |
| Abbasi, MM | 1 |
| Dustar, Y | 1 |
| Javadzadeh, Y | 1 |
| Roth, MJ | 1 |
| Katki, HA | 1 |
| Wei, WQ | 2 |
| Qiao, YL | 2 |
| Bagni, R | 1 |
| Wang, GQ | 1 |
| Whitby, D | 1 |
| Dong, ZW | 2 |
| Gail, MH | 1 |
| Limburg, PJ | 2 |
| Giffen, CA | 1 |
| Taylor, PR | 2 |
| Dawsey, SM | 2 |
| Gravitz, L | 1 |
| Wong, BC | 1 |
| Liu, WD | 1 |
| Feng, GS | 1 |
| Zhang, XD | 1 |
| Li, J | 1 |
| Lu, AP | 1 |
| Xia, HH | 1 |
| Lam, S | 1 |
| Piplani, H | 1 |
| Vaish, V | 1 |
| Sanyal, SN | 1 |
| Hill, R | 1 |
| Tran, LM | 1 |
| Dry, S | 1 |
| Calvopina, JH | 1 |
| Garcia, A | 1 |
| Kim, C | 1 |
| Wang, Y | 1 |
| Donahue, TR | 1 |
| Herschman, HR | 1 |
| Wu, H | 1 |
| Femia, AP | 1 |
| Dolara, P | 1 |
| Salvadori, M | 1 |
| Caderni, G | 1 |
| Muller-Decker, K | 1 |
| Neufang, G | 1 |
| Berger, I | 1 |
| Neumann, M | 1 |
| Marks, F | 1 |
| Furstenberger, G | 1 |
| Mohan, S | 1 |
| Epstein, JB | 1 |
| Hegazi, RA | 1 |
| Mady, HH | 1 |
| Melhem, MF | 1 |
| Sepulveda, AR | 1 |
| Mohi, M | 1 |
| Kandil, HM | 1 |
| Graepler, F | 1 |
| Gregor, M | 1 |
| Lauer, UM | 1 |
| Márquez-Rosado, L | 1 |
| Trejo-Solís, MC | 1 |
| García-Cuéllar, CM | 1 |
| Villa-Treviño, S | 1 |
| Joshi, N | 1 |
| Johnson, LL | 1 |
| Abnet, CC | 1 |
| Kirsch, IR | 1 |
| Feng, L | 2 |
| Wang, Z | 1 |
| Schroeder, CP | 1 |
| Kadara, H | 1 |
| Lotan, D | 1 |
| Woo, JK | 1 |
| Lee, HY | 1 |
| Hong, WK | 1 |
| Lotan, R | 1 |
| Tang, BD | 1 |
| Zeng, ZR | 1 |
| Hu, PJ | 1 |
| Futagami, S | 1 |
| Suzuki, K | 1 |
| Hiratsuka, T | 1 |
| Shindo, T | 1 |
| Hamamoto, T | 1 |
| Tatsuguchi, A | 1 |
| Ueki, N | 1 |
| Shinji, Y | 1 |
| Kusunoki, M | 1 |
| Wada, K | 1 |
| Miyake, K | 1 |
| Gudis, K | 1 |
| Tsukui, T | 1 |
| Sakamoto, C | 1 |
| Heath, EI | 1 |
| Canto, MI | 1 |
| Piantadosi, S | 1 |
| Montgomery, E | 1 |
| Weinstein, WM | 1 |
| Herman, JG | 1 |
| Dannenberg, AJ | 2 |
| Yang, VW | 1 |
| Shar, AO | 1 |
| Hawk, E | 1 |
| Forastiere, AA | 1 |
| Papadimitrakopoulou, VA | 1 |
| William, WN | 1 |
| Lippman, SM | 1 |
| Lee, JJ | 1 |
| Ondrey, FG | 1 |
| Peterson, DE | 1 |
| Atwell, A | 1 |
| El-Naggar, AK | 1 |
| Nathan, CO | 1 |
| Helman, JI | 1 |
| Du, B | 1 |
| Yueh, B | 1 |
| Boyle, JO | 1 |
| Grubbs, CJ | 1 |
| Lubet, RA | 1 |
| Koki, AT | 1 |
| Leahy, KM | 1 |
| Masferrer, JL | 1 |
| Kelloff, GJ | 1 |
| Hill, DL | 1 |
| Seibert, K | 1 |
| Yamada, Y | 1 |
| Yoshimi, N | 1 |
| Hirose, Y | 1 |
| Hara, A | 1 |
| Shimizu, M | 1 |
| Kuno, T | 1 |
| Katayama, M | 1 |
| Qiao, Z | 1 |
| Mori, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention[NCT01192204] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Chemoprevention for Barrett's Esophagus Trial (CBET)[NCT00005878] | Phase 2 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions[NCT00014404] | Phase 2 | 0 participants | Interventional | 2000-10-31 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The remaining oral dysplasia lesion will be inspected at each follow up appointment (every 10-14 days). Biopsies will be immediately conducted on patients with any indication of malignant transformation including indurated, rolled borders, nonhealing ulcers, etc. Accordingly, these patients will withdraw from the trial. Participants will also be monitored for any changes consistent with contact mucositis e.g. soreness and erythema at application site. Clinical photographs were taken for the patients records. Pre treatment and post treatment photographs, with a ruler in place, were used for accurate pre and post treatment size measurement. NOTE: if treatment is beneficial, lesional size will decrease which will be reflected as a negative number. (NCT01192204)
Timeframe: pretreatment and posttreatment (3 months treatment duration)
| Intervention | mm^2 (Mean) |
|---|---|
| 10% FBR Gel | -26.12 |
| Placebo Gel | 18.12 |
Laboratory experiments will be conducted to assess the effects of gel treatment on pre and post loss of heterozygosity (LOH) events at loci associated with tumor suppressor genes. (NCT01192204)
Timeframe: Before and after the 3 month treatment duration
| Intervention | LOH events (Mean) |
|---|---|
| 10% FBR Gel | 0.9 |
| Placebo Gel | 0.4 |
A hemisection of lesional tissue will be conducted before the 3 month treatment to establish a diagnosis and provide a pretreatment baseline for the experimental parameters. Anl excisional biopsy of the treatment site including any remaining residual lesional tissue (excision of oral dysplastic lesions is consistent with current standards of care) will be obtained after 3 months of treatment to provide a posttreatment diagnosis. The 0 to 8 histologic scale was:0=normal with or without hyperkeratosis BEST OUTCOME, 1=atypia, 2=mild dysplasia, 3=mild-moderate dysplasia, 4=moderate dysplasia,5=moderate-severe dysplasia,6=severe dysplasia, 7=carcinoma in situ, 8=invasive oral squamous cell carcinoma (WORST OUTCOME). (NCT01192204)
Timeframe: Before and after the 3 month treatment.
| Intervention | unit on histologic grade scale (Mean) | |
|---|---|---|
| Pretreatment | Posttreatment | |
| 10% FBR Gel | 2.36 | 1.9 |
| Placebo Gel | 2.83 | 2.58 |
3 reviews available for celecoxib and Precancerous Conditions
| Article | Year |
|---|---|
Celecoxib in Cancer Therapy and Prevention - Review.
Topics: Animals; Apoptosis; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Female; Humans | 2019 |
Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous | 2003 |
[Anti-angiogenic therapy for gastrointestinal tumours].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2005 |
9 trials available for celecoxib and Precancerous Conditions
| Article | Year |
|---|---|
Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; China; Clarithromycin; Cyclooxygenase 2; Cyclo | 2015 |
Aberrant crypt foci in the adenoma prevention with celecoxib trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Biomarkers; Celecoxib; C | 2008 |
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase | 2008 |
Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.
Topics: Adult; Aged; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2009 |
Serum cytokine analysis in a positive chemoprevention trial: selenium, interleukin-2, and an association with squamous preneoplastic disease.
Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyt | 2010 |
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; Clarithromycin; Cyclooxygenase 2 Inhibitors; D | 2012 |
Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population.
Topics: Carcinoma, Squamous Cell; Celecoxib; China; Disease Progression; Double-Blind Method; Esophageal Neo | 2006 |
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Topics: Aged; Aged, 80 and over; Barrett Esophagus; Cadherins; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2 | 2007 |
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 | 2008 |
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 | 2008 |
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 | 2008 |
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 | 2008 |
23 other studies available for celecoxib and Precancerous Conditions
| Article | Year |
|---|---|
Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Human papillomavirus 16; Mice, Transgenic; | 2017 |
Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Progre | 2019 |
Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; Disease Progres | 2013 |
Do NSAIDs inhibit growth of precancerous cervical cells in vitro?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Celecoxib; Cell Line; C | 2012 |
Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Body Weight; Celecoxib; C | 2015 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Topics: Adenoma; Antineoplastic Agents; Biomarkers; Celecoxib; Chemoprevention; Clinical Trials as Topic; Co | 2008 |
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitor | 2009 |
The effect of dietary and topical celecoxib on 4-nitroquinoline-1-oxide-induced lingual epithelium alternations in rat.
Topics: 4-Nitroquinoline-1-oxide; Administration, Topical; Analysis of Variance; Animals; Celecoxib; Cycloox | 2009 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I | 2011 |
Dolastatin 15, a mollusk linear peptide, and Celecoxib, a selective cyclooxygenase-2 inhibitor, prevent preneoplastic colonic lesions and induce apoptosis through inhibition of the regulatory transcription factor NF-κB and an inflammatory protein, iNOS.
Topics: Animals; Apoptosis; Blotting, Western; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenas | 2012 |
Cell intrinsic role of COX-2 in pancreatic cancer development.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Membrane; Cyclooxygenase 2; Disease Models, A | 2012 |
Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin.
Topics: 1,2-Dimethylhydrazine; Adenoma; Animals; beta Catenin; Biomarkers, Tumor; Celecoxib; Cell Nucleus; C | 2013 |
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenoma; Animals; Carcinogens; Carcinoma, Squamous Cell; Celecoxib | 2002 |
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice.
Topics: Animals; Celecoxib; Colitis; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Disease Models, Animal | 2003 |
Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Liver Neoplasms; Liver Neoplasms, Experimental; Male; | 2005 |
Chemopreventive effect of celecoxib in oral precancers and cancers.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Carcinogens; Celecoxib; Chemopreven | 2006 |
Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells.
Topics: Anticarcinogenic Agents; Apoptosis; Bronchi; Bronchial Diseases; Celecoxib; Cell Line, Tumor; Cells, | 2006 |
[Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
Topics: Animals; Atrophy; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinopr | 2006 |
Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils.
Topics: Animals; Biomarkers, Tumor; Biopsy, Needle; CDX2 Transcription Factor; Celecoxib; Disease Models, An | 2006 |
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Squamous Cel | 2000 |
Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; beta Catenin; Celecoxib; Cell Division; Cell Nucleus | 2001 |